NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
Taking everything into account, INCY scores 6 out of 10 in our fundamental rating. INCY was compared to 568 industry peers in the Biotechnology industry. INCY scores excellent on profitability, but there are some minor concerns on its financial health. INCY may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, INCY could be worth investigating further for value investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 0.6% | ||
ROE | 0.95% | ||
ROIC | 2.32% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 2.63% | ||
PM (TTM) | 0.77% | ||
GM | 93.2% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | 0.15 | ||
Altman-Z | 4.31 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.97 | ||
Quick Ratio | 1.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 42.73 | ||
Fwd PE | 9.49 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 43.83 | ||
EV/EBITDA | 40.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:INCY (4/21/2025, 3:52:09 PM)
56.41
-1.8 (-3.09%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 42.73 | ||
Fwd PE | 9.49 | ||
P/S | 2.57 | ||
P/FCF | 43.83 | ||
P/OCF | 32.55 | ||
P/B | 3.17 | ||
P/tB | 3.43 | ||
EV/EBITDA | 40.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 0.6% | ||
ROE | 0.95% | ||
ROCE | 2.94% | ||
ROIC | 2.32% | ||
ROICexc | 7.51% | ||
ROICexgc | 9.75% | ||
OM | 2.63% | ||
PM (TTM) | 0.77% | ||
GM | 93.2% | ||
FCFM | 5.87% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | 0.15 | ||
Debt/EBITDA | 0.17 | ||
Cap/Depr | 96.66% | ||
Cap/Sales | 2.03% | ||
Interest Coverage | 250 | ||
Cash Conversion | 166.92% | ||
Profit Quality | 763.68% | ||
Current Ratio | 1.97 | ||
Quick Ratio | 1.94 | ||
Altman-Z | 4.31 |